학술논문
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Document Type
Article
Author
Fizazi, K.; Foulon, S.; Bossi, A.; Carles, J.; Roubaud, G.; McDermott, R.; Fléchon, A.; Tombal, B.; Supiot, S.; Berthold, D.; Ronchin, P.; Kacso, G.; Gravis, G.; Calabro, F.; Berdah, J.-F.; Hasbini, A.; Silva, M.; Thiery-Vuillemin, A.; Latorzeff, I.; Mourey, L.; Laguerre, B.; Abadie-Lacourtoisie, S.; Martin, E.; El Kouri, C.; Escande, A.; Rosello, A.; Magne, N.; Schlurmann, F.; Priou, F.; Chand-Fouche, M.-E.; Freixa, S.V.; Jamaluddin, M.; Rieger, I.
Source
In: The Lancet . (The Lancet, 30 April 2022, 399(10336):1695-1707)
Subject
Language
English
ISSN
1474547X
01406736
01406736